Evra Gedeon Richter Plc. · Authorised · authorised 22 Aug 2002 · ATC G03AA13
Therapeutic indication (EMA)
Female contraception. Evra is intended for women of fertile age. The safety and efficacy has been established in women aged 18 to 45 years.
Active substances
Ethinylestradiol + Norelgestromin
- SFDA 1
- US FDA 6
- EMA 1
- Health Canada 1
- US price lines 1
- NHS prices 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| EVRA TRANSDERMAL PATCHES | 0.6,6 mg,mg | Transdermal patch · Topical | 3 Box | SAR 37.25 | Generic · Prescription | GEDEON RICHTER | Valid |
Indications — CHI Daman Drug Formulary
CONTRACEPTION; ENDOMETRIOSIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| XULANE | 0.035MG/24HR;0.15MG/24HR | film, extended release · transdermal | MYLAN TECHNOLOGIES | Prescription | 16 Apr 2014 |
| ETHINYL ESTRADIOL AND NORELGESTROMIN | 0.035MG/24HR;0.15MG/24HR | film, extended release · transdermal | AMNEAL | Prescription | 25 Feb 2021 |
| ONSURA | 0.035MG/24HR;0.15MG/24HR | film, extended release · transdermal | TEVA PHARMS USA | Prescription | 25 Aug 2021 |
| ETHINYL ESTRADIOL AND NORELGESTROMIN | 0.035MG/24HR;0.15MG/24HR | film, extended release · transdermal | ZYDUS PHARMS | Prescription | 14 Sep 2023 |
| GWYN LO | 0.02MG/24HR;0.22MG/24HR | system · transdermal | VIATRIS SPECIALTY | Prescription | 28 Jul 2026 |
| ORTHO EVRA | 0.035MG/24HR;0.15MG/24HR **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | film, extended release · transdermal | JANSSEN PHARMS | Discontinued | 20 Nov 2001 |
EMA European Union — centrally authorised medicines
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| EVRA | 02248297 | 200 MCG / 24 HOUR; 35 MCG / 24 HOUR | PATCH (EXTENDED-RELEASE) · TRANSDERMAL | SEARCHLIGHT PHARMA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | XULANE 150-35 MCG/DAY PATCH | $37.15513 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Ethinylestradiol 33.9micrograms/24hours / Norelgestromin 203micrograms/24hours transdermal patches | £19.51 | 9 patch | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.